SEC Form 4 · accession 0000905148-18-000555
REATA PHARMACEUTICALS INC · RETA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
R Kent McGaughy Jr.
Director · 10% Owner
Period of report
Jun 13, 2018
Accepted (ET)
Jun 15, 2018 · 8:05 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358762
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $39.48 | Jun 13, 2018 | A | 8,000 | A | — | Jun 13, 2028 | Class B common stock | 8,000 | 8,000 | D |
| Stock Option (right to buy)F3,F1,F2 | $39.48 | Jun 13, 2018 | A | 1,844 | A | — | Jun 13, 2028 | Class B common stock | 1,844 | 1,844 | D |
Explanation of responses
- F1The options vest in 4 equal installments on September 13, 2018, December 13, 2018, March 13, 2019, and June 13, 2019, subject to continued service through each vesting date.
- F2The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
- F3This option was issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of director fees of $48,875.